Compositions, methods, and kits are provided for diagnosing and treating prostate cancer. In particular, cell-free DNA biomarkers have been identified that can be used to aid in diagnosis, selection of treatment, and monitoring of treatment of prostate cancer.

Disclosed is an endocyclic pyrimidinone compound of Formula (I) or a pharmaceutically acceptable salt thereof, which is an entirely new Lp-PLA2 inhibitor useful in treating neurodegeneration-related diseases such as Alzheimer's disease (AD), glaucoma and age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis.

A formulation and method for treating prostate cancer is provided. The method includes use of bromodomain and extra-terminal domain inhibitors (BETi) or combination of BETi and anti-androgen drug to therapeutically target DLX1-positive advanced-stage prostate cancer patients. The formulation for treating prostate cancer relates to disrupting ERG/AR transcriptional circuitry with BETi in combination with anti-androgen drug to attenuate DLX1 expression and its downstream oncogenic effects. The BETi and the combination of BETi and anti-androgen drug yields 60% of tumor regression and remarkable reduction in distant metastases in the preclinical immunodeficient mice bearing DLX1-positive tumors.

A formulation and method for treating prostate cancer is provided. The method includes use of bromodomain and extra-terminal domain inhibitors (BETi) or combination of BETi and anti-androgen drug to therapeutically target DLX1-positive advanced-stage prostate cancer patients. The formulation for treating prostate cancer relates to disrupting ERG/AR transcriptional circuitry with BETi in combination with anti-androgen drug to attenuate DLX1 expression and its downstream oncogenic effects. The BETi and the combination of BETi and anti-androgen drug yields 60% of tumor regression and remarkable reduction in distant metastases in the preclinical immunodeficient mice bearing DLX1-positive tumors.

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.

Compounds of the general formula

##STR00001##

are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.

A composition is based on N-palmitoyl-ethanolamide and Baicalein in the co-micronized form. The includes a mixture of palmitoyl-ethanolamide (PEA) and Baicalein in co-micronized form. The composition is usable for treating benign prostatic hyperplasia.

A composition is based on N-palmitoyl-ethanolamide and Baicalein in the co-micronized form. The includes a mixture of palmitoyl-ethanolamide (PEA) and Baicalein in co-micronized form. The composition is usable for treating benign prostatic hyperplasia.

Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.

Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative diseases, such as Huntington's Disease (HD).